1. Home
  2. BOSC vs CINGW Comparison

BOSC vs CINGW Comparison

Compare BOSC & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOSC
  • CINGW
  • Stock Information
  • Founded
  • BOSC 1990
  • CINGW N/A
  • Country
  • BOSC Israel
  • CINGW United States
  • Employees
  • BOSC N/A
  • CINGW 13
  • Industry
  • BOSC Computer Communications Equipment
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • BOSC Telecommunications
  • CINGW Health Care
  • Exchange
  • BOSC Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • BOSC N/A
  • CINGW N/A
  • IPO Year
  • BOSC 1996
  • CINGW 2021
  • Fundamental
  • Price
  • BOSC $4.52
  • CINGW $0.04
  • Analyst Decision
  • BOSC Strong Buy
  • CINGW
  • Analyst Count
  • BOSC 1
  • CINGW 0
  • Target Price
  • BOSC $5.00
  • CINGW N/A
  • AVG Volume (30 Days)
  • BOSC 428.9K
  • CINGW N/A
  • Earning Date
  • BOSC 05-29-2025
  • CINGW N/A
  • Dividend Yield
  • BOSC N/A
  • CINGW N/A
  • EPS Growth
  • BOSC 35.10
  • CINGW N/A
  • EPS
  • BOSC 0.49
  • CINGW N/A
  • Revenue
  • BOSC $43,688,000.00
  • CINGW N/A
  • Revenue This Year
  • BOSC N/A
  • CINGW N/A
  • Revenue Next Year
  • BOSC N/A
  • CINGW N/A
  • P/E Ratio
  • BOSC $9.29
  • CINGW N/A
  • Revenue Growth
  • BOSC 0.84
  • CINGW N/A
  • 52 Week Low
  • BOSC $2.50
  • CINGW N/A
  • 52 Week High
  • BOSC $5.50
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • BOSC 70.17
  • CINGW N/A
  • Support Level
  • BOSC $3.83
  • CINGW N/A
  • Resistance Level
  • BOSC $5.50
  • CINGW N/A
  • Average True Range (ATR)
  • BOSC 0.26
  • CINGW 0.00
  • MACD
  • BOSC 0.06
  • CINGW 0.00
  • Stochastic Oscillator
  • BOSC 47.59
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: